CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 4.48: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.38%
Annual Rate
CNY 0.30Paid annual
Payout Ratio
18.2%Sustainable
Payback Period
70.3 yr
Last Ex-Dividend
Sep 8, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.32BCNY644.06M · vs all stocks (USD)
Trailing P/E
13.04xvs Biotechnology peers
Revenue (TTM)
1.72BCNY257.25M · vs all stocks (USD)
Profit Margin
19.82%vs Biotechnology peers
Beta
0.5880xvs all stocks
52-Week Change
3.42%vs all stocks
Market Capitalization
4.32BCNY644.06M · vs all stocks (USD)
Enterprise Value
4.19BCNY625.19M · vs all stocks (USD)
Trailing P/E
13.04xvs Biotechnology peers
Forward P/E
16.58xvs Biotechnology peers
Price to Sales (TTM)
2.50xvs Biotechnology peers
Price to Book (MRQ)
1.85xvs Biotechnology peers
Enterprise to Revenue
2.43xvs Biotechnology peers
Enterprise to EBITDA
9.68xvs Biotechnology peers
Gross Margin
35.96%vs Biotechnology peers
Profit Margin
19.82%vs Biotechnology peers
Operating Margin
16.89%vs Biotechnology peers
Return on Assets (TTM)
6.06%vs Biotechnology peers
Return on Equity (TTM)
15.59%vs Biotechnology peers
Revenue (TTM)
1.72BCNY257.25M · vs all stocks (USD)
Revenue per Share (TTM)
8.52CNYUpdated Sep 21, 2026Quarterly Revenue Growth
-3.90%vs Biotechnology peers
Gross Profit (TTM)
600.06MCNY89.54M · vs all stocks (USD)
EBITDA (TTM)
352.85MCNY52.65M · vs all stocks (USD)
Net Income (TTM)
341.73MCNY50.99M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
76.20%vs Biotechnology peers
Operating Cash Flow (TTM)
242.87MCNY36.24M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-118.62MCNY-17.70M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.3000CNYUpdated Sep 21, 2026Trailing Annual Dividend Yield
1.38%vs all stocks
Payout Ratio
18.23%vs Biotechnology peers
Minority Interest (Equity)
12.78MCNYFY2025 · Dec 31, 2025Revenue
1.68BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.16BCNYFY2025 · Dec 31, 2025Gross Profit
520.99MCNYFY2025 · Dec 31, 2025Operating Income
302.25MCNY45.10M · vs all stocks (USD)
Pre-tax Income
288.65MCNYFY2025 · Dec 31, 2025Income Tax Expense
35.17MCNYFY2025 · Dec 31, 2025Net Income
253.49MCNYFY2025 · Dec 31, 2025EBIT
302.27MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
430.38MCNYFY2025 · Dec 31, 2025Research & Development
79.82MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
54.18MCNYFY2025 · Dec 31, 2025Other Operating Expenses
11.78MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.04MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
13.62MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.33CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.29CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
189.64MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
189.64MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
253.49MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-332.68KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
199.73MCNYFY2025 · Dec 31, 2025Free Cash Flow
103.21MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
206.12MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
253.49MCNYFY2025 · Dec 31, 2025Other Non-cash Items
16.93MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-43.45MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-27.23MCNYFY2025 · Dec 31, 2025Capital Expenditures
-96.52MCNYFY2025 · Dec 31, 2025Purchase of Investments
-615.03MCNYFY2025 · Dec 31, 2025Sale of Investments
656.71MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-54.84MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
220.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-368.08MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-49.92MCNYFY2025 · Dec 31, 2025Other Financing Charges
37.76MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-160.24MCNYFY2025 · Dec 31, 2025Shares Outstanding
201.78MSharesUpdated Sep 21, 2026Float Shares
104.38MSharesUpdated Sep 21, 2026% Held by Insiders
47.60%vs all stocks
% Held by Institutions
3.89%vs all stocks
Total Cash (MRQ)
573.18MCNY85.53M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.86CNYUpdated Sep 21, 2026Total Debt (MRQ)
463.83MCNY69.21M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1994xvs Biotechnology peers
Current Ratio (MRQ)
2.05xvs Biotechnology peers
Book Value per Share (MRQ)
11.54CNYUpdated Sep 21, 2026Total Assets
3.01BCNY448.94M · vs all stocks (USD)
Total Current Assets
1.31BCNYFY2025 · Dec 31, 2025Total Liabilities
822.17MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.70BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
81.83MCNYFY2025 · Dec 31, 2025Total Current Liabilities
740.33MCNYFY2025 · Dec 31, 2025Cash
204.83MCNYFY2025 · Dec 31, 2025Cash Equivalents
105.37MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
310.20MCNYFY2025 · Dec 31, 2025Other Short-term Investments
160.33MCNYFY2025 · Dec 31, 2025Accounts Receivable
394.78MCNYFY2025 · Dec 31, 2025Inventory
267.89MCNYFY2025 · Dec 31, 2025Accounts Payable
391.20MCNYFY2025 · Dec 31, 2025Short-term Debt
203.88MCNYFY2025 · Dec 31, 2025Other Current Liabilities
33.94MCNYFY2025 · Dec 31, 2025Long-term Debt
24.72MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
1.75MCNYFY2025 · Dec 31, 2025Common Stock (Book)
202.33MCNYFY2025 · Dec 31, 2025Retained Earnings
469.77MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.19BCNY326.26M · vs all stocks (USD)
Treasury Stock
18.09MCNYFY2025 · Dec 31, 202552-Week Low
19.08CNYUpdated Sep 21, 202652-Week High
32.62CNYUpdated Sep 21, 202652-Week Change
3.42%vs all stocks
Beta
0.5880xvs all stocks
50-Day MA
22.33CNYUpdated Sep 21, 2026200-Day MA
24.01CNYUpdated Sep 21, 2026Avg 10-Day Volume
3.33MSharesUpdated Sep 21, 2026Avg 30-Day Volume
5.08MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
1.64CNYUpdated Sep 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.48: safe zoneNotable
Altman Z-Score: 4.48
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Xiangxue Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Contec Medical Systems Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lionco Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
ProKidney Corp
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Minsheng Healthcare Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Vishee Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jianmin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Shengnuo Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jinhe Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Hengdian Group DMEGC Co., Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Yankershop Food Co., Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Hefei Lifeon Pharmaceutical Co., Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated